Fulvaa 250mg Injection

About

Fulvaa 250mg Injection contains Fulvestrant, an estrogen receptor antagonist used in the treatment of hormone-receptor-positive advanced breast cancer. It works by binding to and degrading the estrogen receptor, thereby blocking the growth-promoting effects of estrogen on cancer cells. This mechanism of action makes it particularly effective in postmenopausal women whose cancer has progressed following prior endocrine therapy.

This medication is administered via intramuscular injection and is a crucial component in the management of metastatic breast cancer, offering a targeted approach to inhibit tumor proliferation. Its clinical utility is well-established in patients who have developed resistance to other anti-estrogen treatments, providing a valuable therapeutic option to improve progression-free survival and overall patient outcomes.

Uses

• Advanced hormone-receptor-positive breast cancer
• Postmenopausal women with breast cancer
• Progression after anti-estrogen therapy
• Metastatic breast cancer treatment

Directions For Use

Administered intramuscularly by a healthcare professional. Follow the prescribed dosing schedule strictly.

Benefits

• Targets estrogen receptors directly
• Slows the growth of hormone-sensitive tumors
• Effective in advanced breast cancer
• Improves progression-free survival
• Offers an alternative to chemotherapy
• Convenient dosing schedule

Side Effects

• Injection site reactions
• Nausea
• Fatigue
• Headache
• Hot flashes
• Bone pain
• Back pain
• Arthralgia
• Peripheral edema
• Asthenia
• Vomiting
• Constipation

Safety Measures

• Alcohol - No specific interaction, but moderation is generally advised.
• Pregnancy - Contraindicated; can cause fetal harm. Effective contraception is required.
• Breastfeeding - Not recommended; potential for serious adverse reactions in breastfed infants.
• Liver - Use with caution; dose adjustment may be necessary in severe hepatic impairment.
• Kidney - Use with caution; no specific dose adjustment for mild to moderate renal impairment.
• Lung - No specific contraindication, but monitor for any new or worsening pulmonary symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.